Edwards Lifesciences
1,246 hedge funds and large institutions have $42.4B invested in Edwards Lifesciences in 2022 Q3 according to their latest regulatory filings, with 109 funds opening new positions, 447 increasing their positions, 459 reducing their positions, and 118 closing their positions.
45% more call options, than puts
Call options by funds: $189M | Put options by funds: $130M
1.33% more ownership
Funds ownership: 81.82% → 83.15% (+1.3%)
3% less repeat investments, than reductions
Existing positions increased: 447 | Existing positions reduced: 459
8% less first-time investments, than exits
New positions opened: 109 | Existing positions closed: 118
2% less funds holding
Funds holding: 1,272 → 1,246 (-26)
12% less capital invested
Capital invested by funds: $48.2B → $42.4B (-$5.8B)
18% less funds holding in top 10
Funds holding in top 10: 22 → 18 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$660M |
| 2 |
Millennium Management
New York
|
+$218M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$212M |
| 4 |
Amundi
Paris,
France
|
+$111M |
| 5 |
Holocene Advisors
New York
|
+$93.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$321M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$216M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$188M |
| 4 |
Bank of New York Mellon
New York
|
-$131M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
-$126M |
EW Hedge Fund Activity: Q3 2022 in Review
1,246 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2022, worth a combined $42.4B — down 12% from $48.2B a quarter earlier.
Sellers outnumbered buyers: 118 funds closed out of EW and 109 opened new positions — a net loss of 9 holders — while 459 trimmed existing stakes and 447 added.
The largest buyer was Janus Henderson Group, adding an estimated $660M. The largest seller was BlackRock, cutting an estimated $321M.
- 1,246 institutional investors held Edwards Lifesciences (EW) as of Q3 2022, down from 1,272 in Q2 2022.
- Funds reported $42.4B of Edwards Lifesciences stock for Q3 2022, down 12% quarter-over-quarter.
- 109 funds opened new Edwards Lifesciences positions in Q3 2022 and 118 closed out, a net change of -9 holders.
- The largest Edwards Lifesciences buyer in Q3 2022 was Janus Henderson Group, an estimated $660M added.
- The largest Edwards Lifesciences seller in Q3 2022 was BlackRock, an estimated $321M sold.
Based on aggregated 13F filings for Q3 2022.